Bayer to buy Perfuse Therapeutics for $300M upfront
Bayer is committing $300 million upfront to buy ophthalmology biotech Perfuse Therapeutics and its mid-stage program targeting the leading causes of blindness. The deal appears to be Bayer’s first pharma M&A ...
May 6, 2026 06:56 AM EDTUpdated 01:00 PM Deals Bayer dips toes back into pharma M&A to buy Perfuse Therapeutics Ayisha Sharma News Reporter Bayer is committing $300 million upfront to buy ophthalmology biotech Perfuse Therapeutics and its mid-stage program targeting the leading causes of blindness. The Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that